{
    "id": "dbpedia_2348_3",
    "rank": 33,
    "data": {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000632-34/DK",
        "read_more_link": "",
        "language": "en",
        "title": "Clinical Trials Register",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.clinicaltrialsregister.eu/ctr-search/img/euFlag.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/printer.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/ema_logo.png",
            "https://www.clinicaltrialsregister.eu/ctr-search/img/hma_logo.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "E.1 Medical condition or disease under investigation E.1.1Medical condition(s) being investigated\n\nAcute hypoxaemic respiratory failure in patients admitted to the intensive care unit\n\nAddendum: Acute hypoxaemic respiratory failure in patients admitted to the intensive care unit with COVID-19\n\nE.1.1.1Medical condition in easily understood language\n\nPatients with acute pulmonary failure and inadequate oxygenation of the blood, admitted to an intensive care unit\n\nAddendum: Concerning COVID-19 patients only Patienter indlagt akut på en intensiv afdeling med lungesvigt\n\nTillæg: Patienter indlagt akut på en intensiv afdeling med lungesvigt og COVID-19\n\nE.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08] MedDRA Classification E.1.2 Medical condition or disease under investigation E.1.2 Medical condition or disease under investigation E.1.3Condition being studied is a rare disease No E.2 Objective of the trial E.2.1Main objective of the trial\n\nTo assess the benefits and harms of two targets of partial pressure of oxygen in arterial blood in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory failure at ICU admission.\n\nAddendum: To assess the benefits and harms of two targets in COVID-19 patients. At belyse fordele og ulemper ved at tilstræbe to forskellige niveauer af iltindhold i blodet, målt ved standard målemetoden på intensiv afdeling, som er ilttrykket i pulsårerne, hos kritisk syge voksne patienter, som indlægges akut på en intensiv afdeling med lungesvigt.\n\nTillæg: At belyse fordele og ulemper ved at tilstræbe to forskellige niveauer af iltindhold i blodet for COVID-19 patienter.\n\nE.2.2Secondary objectives of the trial\n\nTo asses health economic implications of two targets of partial pressure of oxygen in arterial blood in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory failure at ICU admission. Conducted through a health economic analysis at one year follow-up of the last enrolled patient.\n\nTillæg: To asses health economic implications of the two targets in COVID-19 patients. At vurdere de sundhedsøkonomiske omkostninger/besparelser ved at tilstræbe to forskellige niveauer af iltindhold i blodet hos kritisk syge voksne patienter, som indlægges akut på en intensiv afdeling med lungesvigt. Dette planlagt når der er lavet et års opfølgning af den sidste inkluderede patient.\n\nTillæg: At vurdere de sundhedsøkonomiske omkostninger/besparelser ved at tilstræbe to forskellige niveauer af iltindhold i blodet hos COVID-19 patienter.\n\nE.2.3Trial contains a sub-study No E.5 End points E.5.1Primary end point(s)\n\nMortality\n\nAddendum: In COVID-19 patients days alive without the use of respiratory support, renal replacement therapy or circulatory support in the 90-day period in the trial extension. Dødelighed\n\nAddendum: Dage i live uden behandling med respirator, dialyse eller kredsløbsstimulerende medicin i 90 dage efter lodtrækningen for COVID-19 patienter i tillægsstudiet\n\nE.5.1.1Timepoint(s) of evaluation of this end point\n\n90 days post-randomisation\n\nAddendum: Identical. 90 dage efter lodtrækning\n\nTillæg: Identisk.\n\nE.5.2Secondary end point(s)\n\n- Number of patients with one or more SAEs in the ICU after randomisation; SAEs are defined as new episode of shock and new episodes of ischemic events including myocardial or intestinal ischaemia or ischemic stroke in the 90-day period\n\n- Days alive without the use of respiratory support, renal replacement therapy or circulatory support in the 90-day period\n\n- Days alive out of the hospital in the 90-day period\n\n- Mortality 1-year after randomisation\n\n- Health related quality of life (Euroqual, EQ-5D-5L) 1-year after randomisation.\n\n- Cognitive function 1-year after randomisation as assessed using RBANS score in selected sites\n\n- Lung function 1-year after randomisation as assessed using full body plethysmography in selected sites\n\n- A health economic analysis based on the result of the trial and specified (cost-effectiveness versus cost-minimisation analyses)\n\nAddendum:\n\n- 90-day all-cause mortality\n\n- Number of patients with one or more SAEs in the ICU after randomisation; SAEs are defined as new episode of shock and new episodes of ischemic events including myocardial or intestinal ischaemia or ischemic stroke in the 90-day period\n\n- Days alive out of the hospital in the 90-day period\n\n- Mortality 1-year after randomisation\n\n- Health related quality of life (Euroqual, EQ-5D-5L) 1-year after randomisation.\n\n- Cognitive function 1-year after randomisation as assessed using RBANS score in selected sites\n\n- Lung function 1-year after randomisation as assessed using full body plethysmography in selected sites\n\n- A health economic analysis based on the result of the trial and specified (cost-effectiveness versus cost-minimisation analyses) - Nyopståede tilfælde af kredsløbssvigt, nyopståede tegn på vævskade i hjerte, hjerne og tarm i 90 dage efter lodtrækningen\n\n- Dage i live uden behandling med respirator, dialyse eller kredsløbsstimulerende medicin i 90 dage efter lodtrækningen\n\n- Dage i live og udskrevet fra hospitalet i 90 dage efter lodtrækningen\n\n- Dødelighed et år efter lodtrækningen\n\n- Vurdering af livskvalitet og kognitiv funktion (selekterede sites) efter et år efter lodtrækningen\n\n- Overordnede sundhedsøkonomiske analyser et år efter lodtrækningen af den sidste inkluderede patient.\n\nTillæg:\n\n- 90-dages dødelighed\n\n- Nyopståede tilfælde af kredsløbssvigt, nyopståede tegn på vævskade i hjerte, hjerne og tarm i 90 dage efter lodtrækningen\n\n- Dage i live og udskrevet fra hospitalet i 90 dage efter lodtrækningen\n\n- Dødelighed et år efter lodtrækningen\n\n- Vurdering af livskvalitet og kognitiv funktion (selekterede sites) efter et år efter lodtrækningen\n\n- Vurdering af lungefunktion efter 1 år efter lodtrækningen\n\n- Overordnede sundhedsøkonomiske analyser et år efter lodtrækningen af den sidste inkluderede patient.\n\nE.5.2.1Timepoint(s) of evaluation of this end point\n\nSee description in E.5.2 Se beskrivelse i E.5.2\n\nE.6 and E.7 Scope of the trial E.6Scope of the trial E.6.1Diagnosis No E.6.2Prophylaxis No E.6.3Therapy Yes E.6.4Safety No E.6.5Efficacy No E.6.6Pharmacokinetic No E.6.7Pharmacodynamic No E.6.8Bioequivalence No E.6.9Dose response No E.6.10Pharmacogenetic No E.6.11Pharmacogenomic No E.6.12Pharmacoeconomic Yes E.6.13Others No E.7Trial type and phase E.7.1Human pharmacology (Phase I) No E.7.1.1First administration to humans No E.7.1.2Bioequivalence study No E.7.1.3Other No E.7.1.3.1Other trial type description E.7.2Therapeutic exploratory (Phase II) No E.7.3Therapeutic confirmatory (Phase III) No E.7.4Therapeutic use (Phase IV) Yes E.8 Design of the trial E.8.1Controlled Yes E.8.1.1Randomised Yes E.8.1.2Open Yes E.8.1.3Single blind No E.8.1.4Double blind No E.8.1.5Parallel group Yes E.8.1.6Cross over No E.8.1.7Other No E.8.2 Comparator of controlled trial E.8.2.1Other medicinal product(s) No E.8.2.2Placebo No E.8.2.3Other Yes E.8.2.3.1Comparator description\n\nForskellig dosering af ilt. Komperatoren er det højeste oxygeneringsmål. Different dosage of oxygen. The comparator is the highest oxygenation target.\n\nE.8.2.4Number of treatment arms in the trial2 E.8.3 The trial involves single site in the Member State concerned No E.8.4 The trial involves multiple sites in the Member State concerned Yes E.8.4.1Number of sites anticipated in Member State concerned21 E.8.5The trial involves multiple Member States Yes E.8.5.1Number of sites anticipated in the EEA50 E.8.6 Trial involving sites outside the EEA E.8.6.1Trial being conducted both within and outside the EEA Yes E.8.6.2Trial being conducted completely outside of the EEA No E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned\n\nDenmark Finland Iceland Netherlands Norway Switzerland United Kingdom\n\nE.8.9 Initial estimate of the duration of the trial E.8.9.1In the Member State concerned years3 E.8.9.1In the Member State concerned months0 E.8.9.1In the Member State concerned days0 E.8.9.2In all countries concerned by the trial years3 E.8.9.2In all countries concerned by the trial months0 E.8.9.2In all countries concerned by the trial days0 F.1 Age Range F.1.1Trial has subjects under 18 No F.1.1.1In Utero No F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No F.1.1.3Newborns (0-27 days) No F.1.1.4Infants and toddlers (28 days-23 months) No F.1.1.5Children (2-11years) No F.1.1.6Adolescents (12-17 years) No F.1.2Adults (18-64 years) Yes F.1.2.1Number of subjects for this age range: 1554 F.1.3Elderly (>=65 years) Yes F.1.3.1Number of subjects for this age range: 2154 F.2 Gender F.2.1Female Yes F.2.2Male Yes F.3 Group of trial subjects F.3.1Healthy volunteers No F.3.2Patients Yes F.3.3Specific vulnerable populations Yes F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: \"Women of childbearing potential\" and did not include the words \"not using contraception\". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2017-02-14. Yes F.3.3.2Women of child-bearing potential using contraception Yes F.3.3.3Pregnant women No F.3.3.4Nursing women Yes F.3.3.5Emergency situation Yes F.3.3.6Subjects incapable of giving consent personally Yes F.3.3.6.1Details of subjects incapable of giving consent\n\nThe trial will enroll critically ill patients (emergency situations) who will be temporarily incompetent due to the severety of illness or as a consequence of the treatment (sedation and analgesics). Forsøget inkluderer kritisk syge patienter i akutte situationer, disse patienter vil være midlertidigt uden handleevne grundet sygdomssværhedsgraden og/eller behandlingen med bedøvelsesmidler og smertestillende medicin.\n\nF.3.3.7Others No F.4 Planned number of subjects to be included F.4.1In the member state2500 F.4.2 For a multinational trial F.4.2.1In the EEA 3200 F.4.2.2In the whole clinical trial 3708 F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)\n\nNone"
    }
}